Conopeptides as novel options for pain management

Drugs of the Future

Volumn 36, Issue 1, 2011, Pages 25-32

  Daly, N L ^a   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CGX 1160; CONOPEPTIDE; CONOTOXIN; CONTULAKIN G; IMB 007; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; UNCLASSIFIED DRUG; XEN 2174;

ABSENCE OF SIDE EFFECTS; ANALGESIA; CANCER PAIN; CONUS SNAIL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; GAIT DISORDER; HUMAN; MEMORY DISORDER; NERVE INJURY; NERVOUSNESS; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTOPERATIVE PAIN; REVIEW; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; SPINAL NERVE;

EID: 84952985593     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.01.1561066     Document Type: Review

References (72)

1. Adams, D.J., Alewood, P.F., Craik, D.J., Drinkwater, R.D., Lewis, R.J. Conotoxins and their potential pharmaceutical applications. Drug Dev Res 1999, 46(3-4): 219-34.
2. Armishaw, C.J., Alewood, P.F. Conotoxins as research tools and drug leads. Curr Protein Pept Sci 2005, 6(3): 221-40.
3. Han, T.S., Teichert, R.W., Olivera, B.M., Bulaj, G. Conus venoms - A rich source of peptide-based therapeutics. Curr Pharm Des 2008, 14(24): 2462-79.
4. Halai, R., Craik, D.J. Conotoxins: Natural product drug leads. Nat Prod Rep 2009, 26(4): 526-36.
5. Olivera, B.M. Conus peptides: Biodiversity-based discovery and exogenomics. J Biol Chem 2006, 281(42): 31173-7.
6. Olivera, B.M., Teichert, R.W. Diversity of the neurotoxic Conus peptides: A model for concerted pharmacological discovery. Mol Interv 2007, 7(5): 251-60.
7. Marx, U.C., Daly, N.L., Craik, D.J. NMR of conotoxins: Structural features and an analysis of chemical shifts of post-translationally modified amino acids. Magn Reson Chem 2006, 44(Spec. No.): S41-50.
8. Azam, L., McIntosh, J.M. Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. Acta Pharmacol Sin 2009, 30(6): 771-83.
9. Nielsen, K.J., Schroeder, T., Lewis, R. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit 2000, 13(2): 55-70.
10. Prorok, M., Castellino, F.J. Structure-function relationships of the NMDA receptor antagonist conantokin peptides. Curr Drug Targets 2001, 2(3): 313-22.
11. Millard, E.L., Daly, N.L., Craik, D.J. Structure-activity relationships of alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors. Eur J Biochem 2004, 271(12): 2320-6.
12. Dutton, J.L., Craik, D.J. alpha-Conotoxins: Nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads. Curr Med Chem 2001, 8(4): 327-44.
13. Becker, S., Terlau, H. Toxins from cone snails: Properties, applications and biotechnological production. Appl Microbiol Biotechnol 2008, 79(1): 1-9.
14. Bingham, J.P., Mitsunaga, E., Bergeron, Z.L. Drugs from slugs-Past, present and future perspectives of omega-conotoxin research. Chem Biol Interact 2010, 183(1): 1-18.
15. Kaas, Q., Westermann, J.C., Halai, R., Wang, C.K., Craik, D.J. ConoServer, a database for conopeptide sequences and structures. Bioinformatics 2008, 24(3): 445-6.
16. Kaas, Q., Westermann, J.C., Craik, D.J. Conopeptide characterization and classifications: An analysis using ConoServer. Toxicon 2010, 55(8): 1491-509.
17. Miljanich, G.P. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004, 11(23): 3029-40.
18. Kolosov, A., Goodchild, C.S., Cooke, I. CNSB004 (leconotide) causes antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010, 11(2): 262-73.
19. Brust, A., Palant, E., Croker, D.E. et al. chi-Conopeptide pharmacophore development: Toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J Med Chem 2009, 52(22): 6991-7002.
20. Sandall, D.W., Satkunanathan, N., Keays, D.A. et al. A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 2003, 42(22): 6904-11.
21. Clark, R.J., Jensen, J., Nevin, S.T., Callaghan, B.P., Adams, D.J., Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew Chem Int Ed Engl 2010, 49(37): 6545-8.
22. Ekberg, J., Jayamanne, A., Vaughan, C.W. et al. muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A 2006, 103(45): 17030-5.
23. Bulaj, G., Zhang, M.M., Green, B.R. et al. Synthetic muO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity. Biochemistry 2006, 45(23): 7404-14.
24. Bogin, O. Venom peptides and their mimetics as potential drugs. Modulator 2005, 19: 14-20.
25. Olivera, B.M., Cruz, L.J., de Santos, V. et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987, 26(8): 2086-90.
26. Fainzilber, M., van der Schors, R., Lodder, J.C., Li, K.W., Geraerts, W.P., Kits, K.S. New sodium channel-blocking conotoxins also affect calcium currents in Lymnaea neurons. Biochemistry 1995, 34(16): 5364-71.
27. Craig, A.G., Norberg, T, Griffin, D. et al. Contulakin-G, an O-glycosylated invertebrate neurotensin. J Biol Chem 1999, 274(20): 13752-9.
28. Mcintosh, J.M., Olivera, B.M., Cruz, L.J., Gray, W.R. Gamma-carboxyglutamate in a neuroactive toxin. J Biol Chem 1984, 259(23): 14343-6.
29. Haack, J.A., Rivier, J., Parks, T.N., Mena, E.E., Cruz, L.J., Olivera, B.M. Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity. J Biol Chem 1990, 265(11): 6025-9.
30. Basus, V.J., Nadasdi, L., Ramachandran, J., Miljanich, G.P. Solution structure of omega-conotoxin MVIIA using 2D NMR spectroscopy. FEBS Lett 1995, 370(3): 163-9.
31. Kohno, T., Kim, J.I., Kobayashi, K., Kodera, Y., Maeda, T., Sato, K. Three-dimensional structure in solution of the calcium channel blocker omega-conotoxin MVIIA. Biochemistry 1995, 34(32): 10256-65.
32. Nielsen, K.J., Adams, D., Thomas, L., Bond, T., Alewood, P.F., Craik, D.J., Lewis, R.J. Structure-activity relationships of omega-conotoxins MVIIA, MVIIC and 14 loop splice hybrids at N and P/Q-type calcium channels. J Mol Biol 1999, 289(5): 1405-21.
33. Pallaghy, P.K., Nielsen, K.J., Craik, D.J., Norton, R.S. A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides. Protein Sci 1994, 3(10): 1833-9.
34. Craik, D.J., Daly, N.L., Waine, C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001, 39(1): 43-60.
35. Rauck, R.L., Wallace, M.S., Leong, M.S. et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006, 31(5): 393-406.
36. Staats, P.S., Yearwood, T., Charapata, S.G. et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA 2004, 291(1): 63-70.
37. Wallace, M.S., Rauck, R., Fisher, R., Charapata, S.G., Ellis, D., Dissanayake, S. Intrathecal ziconotide for severe chronic pain: Safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008, 106(2): 628-37.
38. Lawson, E.F., Wallace, M.S. Current developments in intraspinal agents for cancer and noncancer pain. Curr Pain Headache Rep 2010, 14(1): 8-16.
39. Ilias, W., Todoroff, B. Optimizing pain control through the use of implantable pumps. Med Dev Evid Res 2008, 1: 41-7.
40. Burton, A.W., Deer, T.R., Wallace, M.S., Rauck, R.L., Grigsby, E. Considerations and methodology for trialing ziconotide. Pain Physician 2010, 13(1): 23-33.
41. Scott, D.A., Wright, C.E., Angus, J.A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002, 451(3): 279-86.
42. Wright, C.E., Robertson, A.D., Whorlow, S.L., Angus, J.A. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 2000, 131(7): 1325-36.
43. Berecki, G., Motin, L., Haythornthwaite, A. et al. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels. Mol Pharmacol 2010, 77(2): 139-48.
44. Daly, N.L., Ekberg, J.A., Thomas, L., Adams, D.J., Lewis, R.J., Craik, D.J. Structures of muO-conotoxins from Conus marmoreus. Inhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian sensory neurons. J Biol Chem 2004, 279(24): 25774-82.
45. Sharpe, I.A., Palant, E., Schroeder, C.I., Kaye, D.M., Adams, D.J., Alewood, P.F., Lewis, R.J. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship. J Biol Chem 2003, 278(41): 40317-23.
46. Satkunanathan, N., Livett, B., Gayler, K., Sandall, D., Down, J., Khalil, Z. Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res 2005, 1059(2): 149-58.
47. Craik, D.J. Seamless proteins tie up their loose ends. Science 2006, 311(5767): 1563-4.
48. Craik, D.J., Daly, N.L., Bond, T., Waine, C. Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 1999, 294(5): 1327-36.
49. Colgrave, M.L., Craik, D.J. Thermal, chemical, and enzymatic stability of the cyclotide kalata Bl: The importance of the cyclic cystine knot. Biochemistry 2004, 43(20): 5965-75.
50. Craik, D.J., Cemazar, M., Daly, N.L. The cyclotides and related macrocyclic peptides as scaffolds in drug design. Curr Opin Drug Discov Devel 2006, 9(2): 251-60.
51. Daly, N.L., Craik, D.J. Design and therapeutic applications of cyclotides. Future Med Chem 2009, 1(9): 1613-22.
52. Jagadish, K., Camarero, J.A. Cyclotides, a promising molecular scaffold for peptide-based therapeutics. Biopolymers 2010, Epub ahead of print.
53. Maqueda, M., Galvez, A., Bueno, M.M., Sanchez-Barrena, M. Peptide AS-48: Prototype of a new class of cyclic bacteriocins. Curr Protein Pept Sci 2004, 5(5): 399-416.
54. Quik, M., McIntosh, J.M. Striatal alpha6* nicotinic acetylcholine receptors: Potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 2006, 316(2): 481-9.
55. Hill, J.M., Oomen, C.J., Miranda, L.P., Bingham, J.P., Alewood, P.F., Craik, D.J. Three-dimensional solution structure of alpha-conotoxin MII by NMR spectroscopy: Effects of solution environment on helicity. Biochemistry 1998, 37(45): 15621-30.
56. Shon, K.J., Koerber, S.C., Rivier, J.E., Olivera, B.M., McIntosh, J.M. Three-dimensional solution structure of alpha-conotoxin MII, an alpha3beta2 neuronal nicotinic acetylcholine receptor-targeted ligand. Biochemistry 1997, 36(50): 15693-700.
57. Clark, R.J., Fischer, H., Dempster, L. et al. Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the alpha-conotoxin MII. Proc Natl Acad Sci U S A 2005, 102(39): 13767-72.
58. Gehrmann, J., Alewood, P.F., Craik, D.J. Structure determination of the three disulfide bond isomers for α-conotoxin GI: A model for the role of disulfide bonds in structural stability. J Mol Biol 1998, 278(2): 401-15.
59. Rogers, J.P., Luginbuhl, P., Shen, G.S., McCabe, R.T., Stevens, R.C., Wemmer, D.E. NMR solution structure of alpha-conotoxin ImI and comparison to other conotoxins specific for neuronal nicotinic acetylcholine receptors. Biochemistry 1999, 38(13): 3874-82.
60. Clark, R.J., Fischer, H., Nevin, S.T., Adams, D.J., Craik, D.J. The synthesis, structural characterization, and receptor specificity of the alpha-conotoxin Vc1.1. J Biol Chem 2006, 281(32): 23254-63.
61. Nicke, A., Loughnan, M.L., Millard, E.L. et al. Isolation, structure, and activity of CID, a novel alpha 4/7-conotoxin with an extended N-terminal sequence. J Biol Chem 2003, 278(5): 3137-44.
62. Clark, R.J., Daly, N.L., Halai, R., Nevin, S.T., Adams, D.J., Craik, D.J. The three-dimensional structure of the analgesic alpha-conotoxin, RgIA. FEBS Lett 2008, 582(5): 597-602.
63. Bennett, G.J., Chung, J.M., Honore, M., Seltzer, Z. Models of neuropathic pain in the rat. Curr Protoc Neurosci 2003, Chapter 9: Unit 9.14.
64. Warder, S.E., Chen, Z., Zhu, Y., Prorok, M., Castellino, F.J., Ni, F. The NMR solution structure of the NMDA receptor antagonist, conantokin-T, in the absence of divalent metal ions. FEBS Lett 1997, 411(1): 19-26.
65. Skjaerbaek, N., Nielsen, K.J., Lewis, R.J., Alewood, P., Craik, D.J. Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy. J Biol Chem 1997, 272(4): 2291-9.
66. Chen, Z., Blandl, T., Prorok, M. et al. Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis. J Biol Chem 1998, 273(26): 16248-58.
67. Jimenez, E. Conantokins: From "sleeper" activity to drug development. Philipp Sci Lett 2009, 2(1): 60-6.
68. Xiao, C., Huang, Y., Dong, M. et al. NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins. Neuropeptides 2008, 42(5-6): 601-9.
69. Kern, S.E., Allen, J., Wagstaff, J., Shafer, S.L., Yaksh, T. The pharmacokinetics of the conopeptide contulakin-G (CGX-1160) after intrathecal administration: An analysis of data from studies in beagles. Anesth Analg 2007, 104(6): 1514-20.
70. Allen, J.W., Hofer, K., McCumber, D. et al. An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs. Anesth Analg 2007, 104(6): 1505-13.
71. Lewis, R.J., Nielsen, K.J., Craik, D.J. et al. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000, 275(45): 35335-44.
72. Koradi, R., Billeter, M., Wüthrich, K. MOLMOL: A program for display and analysis of macromolecular structures. J Mol Graph 1996, 14(1): 51-5, 29-32.